|
US3132171A
(en)
|
1962-06-18 |
1964-05-05 |
Strong Cobb Arner Inc |
3, 4-diphosphatophenyl-alanine and process for making same
|
|
IL58849A
(en)
|
1978-12-11 |
1983-03-31 |
Merck & Co Inc |
Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
|
|
US4543256A
(en)
|
1982-03-17 |
1985-09-24 |
Northeastern University |
(-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
|
|
ATE56958T1
(de)
|
1981-10-16 |
1990-10-15 |
Sandoz Ag |
1,2,3,4,4a,5,10,10a-octahydrobenzo(g)chinolinderivate mit pharmazeutischer wirkung.
|
|
PH22782A
(en)
|
1983-02-01 |
1988-12-12 |
Sandoz Ltd |
Novel pharmaceutical active 1,2,3,4,4a,5,10,10a octahydrobenzo(g)quinoline derivatives
|
|
JPS60172975A
(ja)
|
1984-02-15 |
1985-09-06 |
Sumitomo Chem Co Ltd |
エリスロ−３−（３，４−メチレンジオキシフエニル）セリンの製造方法
|
|
GB2192394A
(en)
|
1986-07-11 |
1988-01-13 |
Glaxo Group Ltd |
Amine derivatives
|
|
IT1226727B
(it)
|
1988-07-29 |
1991-02-05 |
Simes |
Farmaci precursori della dopamina.
|
|
EP0393781B1
(en)
|
1989-04-20 |
1995-02-08 |
ZAMBON GROUP S.p.A. |
Dopamine pro-drug
|
|
WO1990012574A1
(en)
|
1989-04-25 |
1990-11-01 |
Northeastern University |
Dopamine agonist compounds
|
|
IT1271411B
(it)
|
1993-09-14 |
1997-05-28 |
Zambon Spa |
Derivati del 2-ammino-1,2,3,4-tetraidro-naftalene attivi sul sistema cardiovascolare
|
|
US5955468A
(en)
|
1993-12-21 |
1999-09-21 |
Sandoz Ltd. |
Benzo G!quinolines for use in prevention or delay of progressive atrophy of the optic nerve
|
|
TW357143B
(en)
|
1995-07-07 |
1999-05-01 |
Novartis Ag |
Benzo[g]quinoline derivatives
|
|
IT1289979B1
(it)
|
1997-02-26 |
1998-10-19 |
Zambon Spa |
5-idrossimetil-6-idrossi-2-amminotetraline attive come agenti cardiovascolari
|
|
US6410664B1
(en)
|
1997-03-24 |
2002-06-25 |
Cryovac, Inc. |
Catalyst compositions and processes for olefin polymers and copolymers
|
|
GB9902938D0
(en)
|
1999-02-10 |
1999-03-31 |
Novartis Ag |
Organic compounds
|
|
CO5261532A1
(es)
|
1999-11-15 |
2003-03-31 |
Novartis Ag |
Compuestos heterociclicos sililados, procedimiento para la preparacion de estos y composicion farmaceutica que los contiene
|
|
KR20030036157A
(ko)
|
2000-04-07 |
2003-05-09 |
탭 파마슈티칼 프로덕츠 인코포레이티드 |
아포모르핀 유도체 및 이의 사용 방법
|
|
SE0001438D0
(sv)
|
2000-04-18 |
2000-04-18 |
Axon Chemicals Bv |
New chemical compounds and their use in therapy
|
|
NZ524212A
(en)
|
2000-08-11 |
2004-07-30 |
Purdue Research Foundation |
Process for the preparation of dinapsoline
|
|
SE0002934D0
(sv)
|
2000-08-17 |
2000-08-17 |
Axon Biochemicals Bv |
New aporphine esters and in their use in therapy
|
|
SE0102036D0
(sv)
|
2001-06-08 |
2001-06-08 |
Axon Biochemicals Bv |
Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
|
|
PE20030240A1
(es)
|
2001-07-09 |
2003-04-16 |
Novartis Ag |
DERIVADOS DE BENZO [g] QUINOLINA
|
|
JP2005504758A
(ja)
|
2001-08-10 |
2005-02-17 |
パーデュー・リサーチ・ファウンデーション |
キラル・ジナプソリン
|
|
EG24415A
(en)
|
2002-03-07 |
2009-05-25 |
Novartis Ag |
Quinoline derivatives
|
|
JP2005526790A
(ja)
|
2002-03-19 |
2005-09-08 |
ミシェル ホリック |
アポモルフィンおよび類縁体の配糖体およびオルトエステル配糖体誘導体、ならびにそれらの使用方法
|
|
AU2003293423A1
(en)
|
2002-12-06 |
2004-06-30 |
Xenoport, Inc. |
Carbidopa prodrugs and uses thereof
|
|
CN1964713A
(zh)
|
2003-12-23 |
2007-05-16 |
达法尔摩公司 |
多巴胺－受体结合化合物的共同使用
|
|
JP2007532670A
(ja)
|
2004-04-13 |
2007-11-15 |
ザ マクレーン ホスピタル コーポレーション |
Ｒ（−）−１１−ヒドロキシアポルフィン誘導体およびその使用方法
|
|
US20070254906A1
(en)
|
2004-07-21 |
2007-11-01 |
Darpharma, Inc. |
Method of Administration of Dopamine Receptor Agonists
|
|
WO2006056604A1
(en)
|
2004-11-25 |
2006-06-01 |
Evolva Ag |
Levodopa glycosyl derivatives, methods of preparation and use
|
|
US20090124651A1
(en)
|
2007-08-31 |
2009-05-14 |
H. Lundbeck A/S |
Catecholamine derivatives and prodrugs thereof
|
|
TWI404702B
(zh)
|
2007-08-31 |
2013-08-11 |
Lundbeck & Co As H |
兒茶酚胺衍生物和其前藥
|
|
WO2009156458A1
(en)
|
2008-06-27 |
2009-12-30 |
H. Lundbeck A/S |
Novel phenolic and catecholic amines and prodrugs thereof
|
|
TW201036949A
(en)
|
2009-02-27 |
2010-10-16 |
Lundbeck & Co As H |
Treatment of dyskinesia related disorders
|
|
TW201035054A
(en)
|
2009-02-27 |
2010-10-01 |
Lundbeck & Co As H |
Methods of administering (4aR, 10aR)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol and pharmaceutical compositions thereof
|
|
EP2557079A1
(en)
|
2011-08-09 |
2013-02-13 |
Nestec S.A. |
Synthesis of catechin and epicatechin conjugates
|
|
DE102011112496A1
(de)
|
2011-09-07 |
2013-03-07 |
Thanares GmbH |
4-Methylcatecholderivate und deren Verwendung
|
|
CN102746351B
(zh)
|
2012-07-23 |
2018-03-02 |
上海弈柯莱生物医药科技有限公司 |
灯盏花乙素及其类似物的制备方法
|
|
GB201319768D0
(en)
|
2013-11-08 |
2013-12-25 |
Glycosynth Ltd |
Naphthalene derived chromogenic enzyme substrates
|
|
ES2739536T3
(es)
|
2014-10-21 |
2020-01-31 |
Abbvie Inc |
Profármacos de carbidopa y L-dopa y su uso para tratar la enfermedad de Parkinson
|
|
CN105218606B
(zh)
|
2015-10-19 |
2017-12-01 |
昆明理工大学 |
一种制备灯盏乙素的方法
|
|
US20190224220A1
(en)
|
2016-04-20 |
2019-07-25 |
Abbvie Inc. |
Carbidopa and L-Dopa Prodrugs and Methods of Use
|
|
US9920342B2
(en)
|
2016-05-17 |
2018-03-20 |
Divi's Laboratories Limited |
Process for the preparation of Droxidopa
|
|
PT3713933T
(pt)
|
2017-11-24 |
2026-05-19 |
H Lundbeck As |
Novos profrmacos de catecolamina para utilizao no tratamento de doena de parkinson
|
|
US11111263B2
(en)
*
|
2019-05-20 |
2021-09-07 |
H. Lundbeck A/S |
Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
|
|
US11104697B2
(en)
|
2019-05-20 |
2021-08-31 |
H. Lundbeck A/S |
Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
|
|
US11130775B2
(en)
|
2019-05-20 |
2021-09-28 |
H. Lundbeck A/S |
Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
|
|
US11168056B2
(en)
|
2019-05-20 |
2021-11-09 |
H. Lundbeck A/S |
Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
|
|
WO2020234275A1
(en)
*
|
2019-05-21 |
2020-11-26 |
H. Lundbeck A/S |
New catecholamine prodrugs for use in the treatment of parkinson's diseases
|
|
US12391650B2
(en)
|
2019-05-21 |
2025-08-19 |
H. Lundbeck A/S |
Catecholamine prodrugs for use in the treatment of Parkinson's disease
|
|
EP3972600B1
(en)
|
2019-05-21 |
2026-02-18 |
H. Lundbeck A/S |
Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease
|
|
WO2022106352A1
(en)
|
2020-11-17 |
2022-05-27 |
H. Lundbeck A/S |
New catecholamine prodrugs for use in the treatment of parkinson's disease
|